Maspin inhibits cell migration in the absence of protease inhibitory activity.

J Biol Chem

School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, United Kingdom.

Published: December 2002

Maspin is a member of the serpin family of protease inhibitors and is a tumor suppressor gene acting at the level of tumor invasion and metastasis. This in vivo activity correlates with the ability of maspin to inhibit cell migration in vitro. This behavior suggests that maspin inhibits matrix-degrading proteases, such as those of the plasminogen activation system, in a similar manner to the serpin PAI-1. However, there is controversy concerning the protease inhibitory activity of maspin. It is devoid of activity against a wide range of proteases, in common with other non-inhibitory serpins, but has recently been reported to inhibit plasminogen activators associated with cells and other biological surfaces (Sheng, S. J., Truong, B., Fredrickson, D., Wu, R. L., Pardee, A. B., and Sager, R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 499-504; McGowen, R., Biliran, H., Jr., Sager, R., and Sheng, S. (2000) Cancer Res. 60, 4771-4778). We have compared the effects of maspin with those of PAI-1 in a range of situations in which plasminogen activation is potentiated, reflecting the biological context of this proteolytic system: urokinase-type plasminogen activator bound to its receptor on the surface of tumor cells, tissue-type plasminogen activator specifically bound to vascular smooth muscle cells, fibrin, and the prion protein. Maspin was found to have no inhibitory effect in any of these situations, in contrast to the efficient inhibition observed with PAI-1, but nevertheless maspin inhibited the migration of both tumor and vascular smooth muscle cells. We conclude that maspin is a non-inhibitory serpin and that protease inhibition does not account for its activity as a tumor suppressor.

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.C200532200DOI Listing

Publication Analysis

Top Keywords

maspin
9
maspin inhibits
8
cell migration
8
protease inhibitory
8
inhibitory activity
8
activity maspin
8
tumor suppressor
8
plasminogen activation
8
plasminogen activator
8
activator bound
8

Similar Publications

Hyperglycemia and hyperglycosuria, two primary characteristics of diabetes mellitus, may increase the risk of cancer initiation, particularly for bladder cancer. The effectiveness of metformin, a common antidiabetic agent, is determined by its ability to induce growth differentiation factor 15 (GDF15). However, the mechanism of the GDF15 in relation to glucose, which influences the tumor microenvironment in the human bladder, is not fully understood.

View Article and Find Full Text PDF

Mammary serine protease inhibitor (maspin) is a tumor suppressor protein downregulated during carcinogenesis and cancer progression; cytoplasmic-only maspin expression is an independent, unfavorable prognostic indicator in patients with lung squamous cell carcinoma (LUSC). We hypothesized that the cytoplasmic-only localization of maspin has tumor-promoting functions in LUSC. The subcellular localization of maspin and the invasive capability of LUSC cell lines were investigated using RNA sequencing (RNA-seq), Western blotting, and siRNA transfection.

View Article and Find Full Text PDF

Application of urine proteomics in the diagnosis and treatment effectiveness monitoring of early-stage Mycosis Fungoides.

Clin Proteomics

August 2024

Department of Dermatology, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Dongcheng District, Beijing, 100730, China.

Article Synopsis
  • Mycosis fungoides (MF) is a common skin lymphoma often misdiagnosed due to its non-specific early symptoms, leading to treatment delays; researchers aimed to find urinary biomarkers for early detection of MF through proteomic analysis.
  • A study involving 13 early-stage MF patients treated with interferon α-2a and phototherapy analyzed urine samples before and after treatment, comparing them with healthy controls to identify differentially expressed proteins.
  • The results revealed 41 proteins with significant expression changes, with certain proteins like Serpin B5, epidermal growth factor (EGF), and RhoA showing lower levels in untreated MF patients, but these levels normalized after treatment, indicating potential biomarkers for monitoring MF.
View Article and Find Full Text PDF

Background: Colorectal cancer remains to be the third leading cause of cancer mortality rates. Despite the diverse effects of the miRNA cluster located in of 8q24.21 across various tumors, the specific biological function in colorectal cancer has not been clarified.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!